IFN-γ treatment protocol for MHC-I^lo/PD-L1⁺ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential

Abstract

BackgroundMany cancer cells express a major histocompatibility complex class I low/ programmed cell death 1 ligand 1 positive (MHC-Ilo/PD-L1+) cell surface profile. For immunotherapy, there is, thus, an urgent need to restore presentation competence of cancer cells with defects in MHC-I processing/presentation combined with immune interventions that tackle the tumor-initiated PD-L1/PD-1 signaling axis. Using pancreatic ductal adenocarcinoma cells (PDACCs) as a model, we here explored if (and how) expression/processing of tumor antigens via transporters associated with antigen processing (TAP) affects priming of CD8 T cells in PD-1/PD-L1-competent/-deficient mice.MethodsWe generated tumor antigen-expressing vectors, immunized TAP-competent/-deficient mice and determined de novo primed CD8 T-cell frequencies by flow cytometry. Similarly, we explored the antigenicity and PD-L1/PD-1 sensitivity of PDACCs versus interferon-γ (IFN-γ)-treated PDACCs in PD-1/PD-L1-competent/deficient mice. The IFN-γ-induced effects on gene and cell surface expression profiles were determined by microarrays and flow cytometry.ResultsWe identified two antigens (cripto-1 and an endogenous leukemia virus-derived gp70) that were expressed in the Endoplasmic Reticulum (ER) of PDACCs and induced CD8 T-cell responses either independent (Cripto-1:Kb/Cr16-24) or dependent (gp70:Kb/p15E) on TAP by DNA immunization. IFN-γ-treatment of PDACCs in vitro upregulated MHC-I- and TAP- but also PD-L1-expression. Mechanistically, PD-L1/PD-1 signaling was superior to the reconstitution of MHC-I presentation competence, as subcutaneously transplanted IFN-γ-treated PDACCs developed tumors in C57BL/6J and PD-L1-/- but not in PD-1-/- mice. Using PDACCs, irradiated at day 3 post-IFN-γ-treatment or PD-L1 knockout PDACCs as vaccines, we could selectively bypass upregulation of PD-L1, preferentially induce TAP-dependent gp70:Kb/p15E-specific CD8 T cells associated with a weakened PD-1+ exhaustion phenotype and reject consecutively injected tumor transplants in C57BL/6J mice.ConclusionsThe IFN-γ-treatment protocol is attractive for cell-based immunotherapies, because it restores TAP-dependent antigen processing in cancer cells, facilitates priming of TAP-dependent effector CD8 T-cell responses without additional check point inhibitors and could be combined with genetic vaccines that complement priming of TAP-independent CD8 T cells.

The impact of tumor immunogenicity on cancer pain phenotype using syngeneic oral cancer mouse models

“…To first determine the immunogenicity of different cell lines, we quantified inducible genes encoding murine major histocompatibility complex (MHC) class I molecules in four mouse-derived cell lines (MOC1, MOC2, MOC22, NOOC1) in response to IFN-γ exposure ( 24 , 25 ). Three different passages of each line were grown to 50% confluency and then treated with either 100 ng/mL IFN-γ or vehicle (0.1% BSA) for 24 h. Cells were then collected and probed for MHC class-I transcription factor, H2k1 , using RT-qPCR; relative expression was normalized to housekeeping gene, beta-actin.…”

An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts

“…Increasing evidence constantly confirmed that IFN-γ plays a critical role in the tumorigenicity and immunogenicity of various cancers (Jorgovanovic et al, 2020;Stifter et al, 2020). Specially, IFNγ is a cytokine that physiologically promotes innate and adaptive immune responses, while preventing the development of primary and transplanted tumors (Burke and Young, 2019).…”

Glucose-Restricted Diet Regulates the Tumor Immune Microenvironment and Prevents Tumor Growth in Lung Adenocarcinoma

“…It increases and prolongs the expression of antigen presentation via induction of MHC class I molecules. Furthermore, it enhances NK cells, CTLs activity and induces regulatory T cell fragility (61,62). However, IFN-g induces PD-L1 expression in tumor cells, which is one of the most important tumor immune evasion mechanisms in NSCLC.…”